Martin Uhl
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
Neurooncology Working Group of the German Cancer Society, Simon M, Tonn J, Stummer W, Schaub C, Weller J, Kebir S, Schäfer N, Stuplich M, Vatter H, Misch M, Keil V, Nelles M, Glas M, Coch C, Pietsch T, Hattingen E, Schmid M, Fimmers R, Weller M, Wick W, Coenen M, Urbach H, Vajkoczy P, Galldiks N, Bullinger L, Goldbrunner R, Grauer O, Krex D, Kortmann R, Hau P, Sabel M, Schlegel U, Steinbach J, Mack F, Tzaridis T, Schnell O, Bähr O, Renovanz M, Weyerbrock A, Brehmer S, Suchorska B, Schmidt-Graf F, Ringel F, Kowalski T, Tabatabai G, Seidel C, Uhl M, Herrlinger U. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet 2019; 393:678-688.
14.02.2019Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
14.02.2019Lancet 2019; 393:678-688
Neurooncology Working Group of the German Cancer Society, Simon Matthias, Tonn Jörg-Christian, Stummer Walter, Schaub Christina, Weller Johannes, Kebir Sied, Schäfer Niklas, Stuplich Moritz, Vatter Hartmut, Misch Martin, Keil Vera C, Nelles Michael, Glas Martin, Coch Christoph, Pietsch Torsten, Hattingen Elke, Schmid Matthias, Fimmers Rolf, Weller Michael, Wick Wolfgang, Coenen Martin, Urbach Horst, Vajkoczy Peter, Galldiks Norbert, Bullinger Lars, Goldbrunner Roland, Grauer Oliver, Krex Dietmar, Kortmann Rolf-Dieter, Hau Peter, Sabel Michael, Schlegel Uwe, Steinbach Joachim Peter, Mack Frederic, Tzaridis Theophilos, Schnell Oliver, Bähr Oliver, Renovanz Miriam, Weyerbrock Astrid, Brehmer Stefanie, Suchorska Bogdana, Schmidt-Graf Friederike, Ringel Florian, Kowalski Thomas, Tabatabai Ghazaleh, Seidel Clemens, Uhl Martin, Herrlinger Ulrich
Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.
Schäfer N, Proescholdt M, Steinbach J, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch M, Uhl M, Grau S, Hänel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U. Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. Neuro Oncol 2018; 20:975-985.
18.06.2018Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.
18.06.2018Neuro Oncol 2018; 20:975-985
Schäfer Niklas, Proescholdt Martin, Steinbach Joachim P, Weyerbrock Astrid, Hau Peter, Grauer Oliver, Goldbrunner Roland, Friedrich Franziska, Rohde Veit, Ringel Florian, Schlegel Uwe, Sabel Michael, Ronellenfitsch Michael W, Uhl Martin, Grau Stefan, Hänel Mathias, Schnell Oliver, Krex Dietmar, Vajkoczy Peter, Tabatabai Ghazaleh, Mack Frederic, Schaub Christina, Tzaridis Theophilos, Nießen Michael, Kebir Sied, Leutgeb Barbara, Urbach Horst, Belka Claus, Stummer Walter, Glas Martin, Herrlinger Ulrich
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial
Herrlinger U, Kortmann R, Mehdorn M, Tüttenberg J, Mayer-Steinacker R, Fietkau R, Brehmer S, Mack F, Stuplich M, Kebir S, Kohnen R, Dunkl E, Leutgeb B, Proescholdt M, Pietsch T, Urbach H, Belka C, Stummer W, Gerlach R, Vajkoczy P, Schäfer N, Steinbach J, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch M, Uhl M, Maciaczyk J, Grau S, Schnell O, Hänel M, Krex D, Glas M. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. J Clin Oncol 2016; 34:1611-9.
14.03.2016Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial
14.03.2016J Clin Oncol 2016; 34:1611-9
Herrlinger Ulrich, Kortmann Rolf-Dieter, Mehdorn Maximilian, Tüttenberg Jochen, Mayer-Steinacker Regine, Fietkau Rainer, Brehmer Stefanie, Mack Frederic, Stuplich Moritz, Kebir Sied, Kohnen Ralf, Dunkl Elmar, Leutgeb Barbara, Proescholdt Martin, Pietsch Torsten, Urbach Horst, Belka Claus, Stummer Walter, Gerlach Rüdiger, Vajkoczy Peter, Schäfer Niklas, Steinbach Joachim P, Weyerbrock Astrid, Hau Peter, Goldbrunner Roland, Friedrich Franziska, Rohde Veit, Ringel Florian, Schlegel Uwe, Sabel Michael, Ronellenfitsch Michael W, Uhl Martin, Maciaczyk Jaroslaw, Grau Stefan, Schnell Oliver, Hänel Mathias, Krex Dietmar, Glas Martin